# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
JMP Securities analyst Roy Buchanan reiterates CureVac (NASDAQ:CVAC) with a Market Outperform and maintains $16 price target.
Preliminary immunogenicity results demonstrate induction of cancer antigen-specific T-cell responses in 77% of evaluable patien...
GSK announced positive phase 2 trial results for its mRNA seasonal flu vaccine, showing strong immune.
JMP Securities analyst Roy Buchanan maintains CureVac (NASDAQ:CVAC) with a Market Outperform and lowers the price target fro...
First patient administered in dose-confirmation Part B of Phase 1 study with mRNA-based, multiepitope cancer vaccine candidate ...
New trial date for U.S. patent litigation set for March 3, 2025, following settlement with Acuitas Therapeutics. First...
JMP Securities analyst Roy Buchanan reiterates CureVac (NASDAQ:CVAC) with a Market Outperform and maintains $18 price target.